Abstract
BACKGROUND: Androgenetic alopecia (AGA) is a common age-related hair loss condition influenced by genetics and androgen activity. AIM: This study evaluated the safety and efficacy of Cuticapil Stem Hair Serum in improving hair loss in AGA patients. METHOD: This multicenter, prospective, observational study assessed the real-world efficacy and safety of Cuticapil Stem Hair Serum in patients with androgenetic alopecia. A total of 60 subjects were evaluated, with the Cuticapil and Standard of Care groups compared using the Mann-Whitney and Wilcoxon signed-rank tests. Key assessments included the hair pull test, global photographic analysis, and hair shedding count. No adverse events were reported, reinforcing the serum's favorable safety profile. RESULT: The Cuticapil + SoC treatment group consistently showed higher mean ranks across multiple parameters compared to the SoC-only group. The addition of Cuticapil Serum to SoC significantly reduced hair shedding (p = 0.0220). In the Hair Pull Test, the Cuticapil + SoC group had a lower mean rank (26.97) than SoC alone (34.03) (p = 0.0196), indicating greater efficacy. Global photography analysis showed a higher mean rank of 36.13 in the Cuticapil + SoC group compared to 24.87 in the SoC group (p = 0.0057), further supporting its effectiveness. CONCLUSION: Cuticapil Stem Hair Serum, when used in addition to standard care, significantly enhances hair growth and reduces hair fall in patients with mild to moderate Androgenetic Alopecia and Female Pattern Hair Loss. It showed superior results in promoting hair growth, reducing shedding, improving hair density, appearance, and managing hair loss.